Shares of Moderna Inc. (MRNA) surged approximately 10% on Friday, closing at $53.41, after the biotech firm announced it is initiating research into vaccines targeting hantaviruses. The move comes as a rare and deadly outbreak of Andes virus, linked to the MV Hondius cruise ship, has drawn global attention. The stock hit an intraday high of $57.77 earlier in the session.
The outbreak, which has resulted in eight reported cases and three deaths according to the World Health Organization (WHO), has put Moderna's mRNA platform back under the spotlight. Five of the cases have been confirmed as hantavirus infections, specifically the Andes virus strain, which is unique among hantaviruses for its ability to spread from person to person through prolonged close contact.
Moderna's foray into hantavirus vaccines is still in its infancy. The company is collaborating with Korea University's Vaccine Innovation Center, a partnership that predates the current outbreak. Under the agreement, the Korean institution provided hantavirus antigen sequence data, while Moderna supplied mRNA substances to support initial research. Francesca Ceddia, Moderna's chief medical officer, stated that the collaboration aims to 'strengthen mRNA vaccine research and development capabilities in Korea.' Heejin Cheong, head of the Vaccine Innovation Center, confirmed that both parties plan to continue their work on an mRNA-based hantavirus vaccine.
Despite the stock's rally, analysts caution that a commercial product is still years away. Evercore ISI analysts, cited by Barron's, noted that hantavirus cases are rare, and the revenue potential from this program is minimal in the near term. Moderna is still grappling with the aftermath of its COVID-19 vaccine success, and investors are keen to see the company diversify its pipeline.
Public health officials are urging a measured response. WHO Director-General Tedros Adhanom Ghebreyesus described the situation as serious but assessed the overall public health risk as low. He warned that additional cases could emerge due to the virus's incubation period. Dr. Michael Osterholm, director of the University of Minnesota's Center for Infectious Diseases Research and Policy, told STAT that 'it's not the next pandemic' and that proper respiratory protection should be sufficient to control transmission.
The outbreak has prompted swift governmental action. The U.S. State Department is organizing a repatriation flight for 17 American passengers aboard the Dutch cruise ship, which is scheduled to dock in Tenerife, Spain.
Moderna's stock also received a boost from positive news elsewhere in its pipeline. Reuters reported this week that the company's experimental seasonal flu vaccine outperformed a standard-dose flu shot from GSK in a late-stage trial involving over 40,000 adults aged 50 and older. The U.S. Food and Drug Administration is expected to decide on that vaccine by August 5.
Bernstein analyst Courtney Breen, commenting on Moderna's first-quarter results, told Reuters that 'near-term, things appear to have stabilized' and that the focus is shifting toward non-COVID opportunities. For Moderna, the key question is whether each new infectious disease headline can reignite investor enthusiasm for a company still navigating the post-pandemic landscape.
